suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

January 29, 2022

Study Completion Date

April 15, 2022

Conditions
COVID-19Virus DiseasesCorona Virus InfectionLower Respiratory Tract Infection Viral
Interventions
DRUG

Anakinra

Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days

Trial Locations (28)

11144

Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens

11526

1st Department of InternalMedicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens

11527

1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens

1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens

1st University Departmentof Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseasesof Athens, Athens

2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens

3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens

Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens

11528

Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens

15126

COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi

26504

Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Pátrai

41334

Department of Internal Medicine, University General Hospital of Larissa, Larissa

45500

1st Department of Internal Medicine, General University Hospital of Ioannina, Ioannina

49100

Department of Infectious Diseases, General Hospital of Kerkira, Corfu

54621

1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki

60100

Department of Internal Medicine, General Hospital of Katerini, Katerini

68100

2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupoli

Unknown

1st Department of Internal Medicine Amalia Fleming General Hospital, Athens

1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens

1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION, Athens

1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO, Athens

2nd Department of Internal Medicine, 251 Air Force General Hospital, Athens

2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens

3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S., Athens

5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens

Department of Internal Medicine, General Hospital of Athens ELPIS, Athens

Department of Internal Medicine, General Hospital of Larisa KOUTLIMBANEIO & ΤΡΙΑΝΤΑFΥLLΕΙΟ, Larissa

2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO, Piraeus

All Listed Sponsors
lead

Hellenic Institute for the Study of Sepsis

OTHER

NCT04357366 - suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE) | Biotech Hunter | Biotech Hunter